<?xml version="1.0" encoding="UTF-8"?>
<wcm:root xmlns:wcm="http://www.stellent.com/wcm-data/ns/8.0.0">
  <wcm:element name="MainContent">&lt;p&gt;&lt;font face="Melior" size="4"&gt;&lt;p style="line-height: 120%"&gt;&lt;b&gt;&lt;span style="font-size: 7.5pt; color: #484138; line-height: 120%; font-family: &amp;quot;Calibri&amp;quot;,&amp;quot;sans-serif&amp;quot;; mso-bidi-font-family: Arial; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin"&gt;&amp;nbsp;&lt;o:p&gt;&lt;/o:p&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p class="MsoNoSpacing" style="margin: 0in 0in 0pt"&gt;&lt;b style="mso-bidi-font-weight: normal"&gt;&lt;span style="font-size: 14pt"&gt;&lt;font color="#000000"&gt;&lt;font face="Calibri"&gt;DEPARTMENT OF HEALTH AND HUMAN SERVICES&lt;o:p&gt;&lt;/o:p&gt;&lt;/font&gt;&lt;/font&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p class="MsoNoSpacing" style="margin: 0in 0in 0pt"&gt;&lt;b style="mso-bidi-font-weight: normal"&gt;&lt;span style="font-size: 14pt"&gt;&lt;font color="#000000"&gt;&lt;font face="Calibri"&gt;Food and Drug Administration&lt;o:p&gt;&lt;/o:p&gt;&lt;/font&gt;&lt;/font&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p class="MsoNoSpacing" style="margin: 0in 0in 0pt"&gt;&lt;span style="font-size: 14pt"&gt;&lt;font color="#000000"&gt;&lt;font face="Calibri"&gt;[Docket No. FDA&amp;ndash;2010&amp;ndash;N&amp;ndash;0001]&lt;o:p&gt;&lt;/o:p&gt;&lt;/font&gt;&lt;/font&gt;&lt;/span&gt;&lt;/p&gt;&lt;p class="MsoNoSpacing" style="margin: 0in 0in 0pt"&gt;&lt;b style="mso-bidi-font-weight: normal"&gt;&lt;span style="font-size: 14pt"&gt;&lt;font color="#000000"&gt;&lt;font face="Calibri"&gt;Gastroenterology and Urology Devices Panel of the Medical Devices&lt;o:p&gt;&lt;/o:p&gt;&lt;/font&gt;&lt;/font&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p class="MsoNoSpacing" style="margin: 0in 0in 0pt"&gt;&lt;b style="mso-bidi-font-weight: normal"&gt;&lt;span style="font-size: 14pt"&gt;&lt;font color="#000000"&gt;&lt;font face="Calibri"&gt;Advisory Committee; Notice of Meeting&lt;o:p&gt;&lt;/o:p&gt;&lt;/font&gt;&lt;/font&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p class="MsoNoSpacing" style="margin: 0in 0in 0pt"&gt;&lt;font color="#000000"&gt;&lt;font face="Calibri"&gt;&lt;b style="mso-bidi-font-weight: normal"&gt;&lt;span style="font-size: 14pt"&gt;AGENCY: &lt;/span&gt;&lt;/b&gt;&lt;span style="font-size: 14pt"&gt;Food and Drug Administration, HHS.&lt;o:p&gt;&lt;/o:p&gt;&lt;/span&gt;&lt;/font&gt;&lt;/font&gt;&lt;/p&gt;&lt;p class="MsoNoSpacing" style="margin: 0in 0in 0pt"&gt;&lt;font color="#000000"&gt;&lt;font face="Calibri"&gt;&lt;b style="mso-bidi-font-weight: normal"&gt;&lt;span style="font-size: 14pt"&gt;ACTION: &lt;/span&gt;&lt;/b&gt;&lt;span style="font-size: 14pt"&gt;Notice.&lt;b style="mso-bidi-font-weight: normal"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/b&gt;&lt;/span&gt;&lt;/font&gt;&lt;/font&gt;&lt;/p&gt;&lt;p class="MsoNoSpacing" style="margin: 0in 0in 0pt"&gt;&lt;font face="Calibri" color="#000000" size="3"&gt;This notice announces a forthcoming meeting of a public advisory&lt;/font&gt;&lt;/p&gt;&lt;p class="MsoNoSpacing" style="margin: 0in 0in 0pt"&gt;&lt;font face="Calibri" color="#000000" size="3"&gt;committee of the Food and Drug Administration (FDA). The meeting will be&lt;/font&gt;&lt;/p&gt;&lt;p class="MsoNoSpacing" style="margin: 0in 0in 0pt"&gt;&lt;font face="Calibri" color="#000000" size="3"&gt;open to the public.&lt;/font&gt;&lt;/p&gt;&lt;p class="MsoNoSpacing" style="margin: 0in 0in 0pt"&gt;&lt;font size="3"&gt;&lt;font color="#000000"&gt;&lt;font face="Calibri"&gt;&lt;i&gt;Name of Committee&lt;/i&gt;: Gastroenterology and Urology Devices Panel of the&lt;/font&gt;&lt;/font&gt;&lt;/font&gt;&lt;/p&gt;&lt;p class="MsoNoSpacing" style="margin: 0in 0in 0pt"&gt;&lt;font face="Calibri" color="#000000" size="3"&gt;Medical Devices Advisory Committee.&lt;/font&gt;&lt;/p&gt;&lt;p class="MsoNoSpacing" style="margin: 0in 0in 0pt"&gt;&lt;font size="3"&gt;&lt;font color="#000000"&gt;&lt;font face="Calibri"&gt;&lt;i&gt;General Function of the Committee&lt;/i&gt;: To provide advice and&lt;/font&gt;&lt;/font&gt;&lt;/font&gt;&lt;/p&gt;&lt;p class="MsoNoSpacing" style="margin: 0in 0in 0pt"&gt;&lt;font face="Calibri" color="#000000" size="3"&gt;recommendations to the agency on FDA&amp;rsquo;s regulatory issues.&lt;/font&gt;&lt;/p&gt;&lt;p class="MsoNoSpacing" style="margin: 0in 0in 0pt"&gt;&lt;font size="3"&gt;&lt;font color="#000000"&gt;&lt;font face="Calibri"&gt;&lt;i&gt;Date and Time&lt;/i&gt;: The meeting will be held on December 2 and 3, 2010,&lt;/font&gt;&lt;/font&gt;&lt;/font&gt;&lt;/p&gt;&lt;p class="MsoNoSpacing" style="margin: 0in 0in 0pt"&gt;&lt;font face="Calibri" color="#000000" size="3"&gt;from 8 a.m. to 6 p.m.&lt;/font&gt;&lt;/p&gt;&lt;p class="MsoNoSpacing" style="margin: 0in 0in 0pt"&gt;&lt;font size="3"&gt;&lt;font color="#000000"&gt;&lt;font face="Calibri"&gt;&lt;i&gt;Location&lt;/i&gt;: Hilton Washington DC North/Gaithersburg, Ballroom, 620 Perry&lt;/font&gt;&lt;/font&gt;&lt;/font&gt;&lt;/p&gt;&lt;p class="MsoNoSpacing" style="margin: 0in 0in 0pt"&gt;&lt;font face="Calibri" color="#000000" size="3"&gt;Pkwy., Gaithersburg, MD.&lt;/font&gt;&lt;/p&gt;&lt;p class="MsoNoSpacing" style="margin: 0in 0in 0pt"&gt;&lt;font size="3"&gt;&lt;font color="#000000"&gt;&lt;font face="Calibri"&gt;&lt;i&gt;Contact Person&lt;/i&gt;: Margaret McCabe-Janicki, Food and Drug Administration,&lt;/font&gt;&lt;/font&gt;&lt;/font&gt;&lt;/p&gt;&lt;p class="MsoNoSpacing" style="margin: 0in 0in 0pt"&gt;&lt;font face="Calibri" color="#000000" size="3"&gt;Center for Devices and Radiological Health, 10903 New Hampshire Ave., Bldg.&lt;/font&gt;&lt;/p&gt;&lt;p class="MsoNoSpacing" style="margin: 0in 0in 0pt"&gt;&lt;font face="Calibri" color="#000000" size="3"&gt;66, rm. 1535, Silver Spring, MD 20993&amp;ndash;0002, 301&amp;ndash;796&amp;ndash;7029, or FDA Advisory&lt;/font&gt;&lt;/p&gt;&lt;p class="MsoNoSpacing" style="margin: 0in 0in 0pt"&gt;&lt;font face="Calibri" color="#000000" size="3"&gt;Committee Information Line, 1&amp;ndash;800&amp;ndash;741&amp;ndash;8138 (301&amp;ndash;443&amp;ndash;0572 in the&lt;/font&gt;&lt;/p&gt;&lt;p class="MsoNoSpacing" style="margin: 0in 0in 0pt"&gt;&lt;font face="Calibri" color="#000000" size="3"&gt;Washington, DC area), code 3014512523. Please call the Information Line for&lt;/font&gt;&lt;/p&gt;&lt;p class="MsoNoSpacing" style="margin: 0in 0in 0pt"&gt;&lt;font size="3"&gt;&lt;font color="#000000"&gt;&lt;font face="Calibri"&gt;up-to-date information on this meeting. A notice in the &lt;b&gt;Federal Register &lt;/b&gt;about&lt;span style="font-size: 9.5pt"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/span&gt;&lt;/font&gt;&lt;/font&gt;&lt;/font&gt;&lt;/p&gt;&lt;p class="MsoNoSpacing" style="margin: 0in 0in 0pt"&gt;&lt;font size="3"&gt;&lt;font color="#000000"&gt;&lt;font face="Calibri"&gt;last minute modifications that impact a previously announced advisory&lt;span style="mso-bidi-font-size: 9.5pt"&gt;&lt;o:p&gt;&lt;/o:p&gt;&lt;/span&gt;&lt;/font&gt;&lt;/font&gt;&lt;/font&gt;&lt;/p&gt;&lt;p class="MsoNoSpacing" style="margin: 0in 0in 0pt"&gt;&lt;font face="Calibri" color="#000000" size="3"&gt;committee meeting cannot always be published quickly enough to provide&lt;/font&gt;&lt;/p&gt;&lt;p class="MsoNoSpacing" style="margin: 0in 0in 0pt"&gt;&lt;font face="Calibri" color="#000000" size="3"&gt;timely notice. Therefore, you should always check the agency&amp;rsquo;s Web site and&lt;/font&gt;&lt;/p&gt;&lt;p class="MsoNoSpacing" style="margin: 0in 0in 0pt"&gt;&lt;font face="Calibri" color="#000000" size="3"&gt;call the appropriate advisory committee hot line/phone line to learn about&lt;/font&gt;&lt;/p&gt;&lt;p class="MsoNoSpacing" style="margin: 0in 0in 0pt"&gt;&lt;font face="Calibri" color="#000000" size="3"&gt;possible modifications before coming to the meeting.&lt;/font&gt;&lt;/p&gt;&lt;p class="MsoNoSpacing" style="margin: 0in 0in 0pt"&gt;&lt;font size="3"&gt;&lt;font color="#000000"&gt;&lt;font face="Calibri"&gt;&lt;i&gt;Agenda&lt;/i&gt;: On December 2, 2010, the committee will discuss, make&lt;/font&gt;&lt;/font&gt;&lt;/font&gt;&lt;/p&gt;&lt;p class="MsoNoSpacing" style="margin: 0in 0in 0pt"&gt;&lt;font face="Calibri" color="#000000" size="3"&gt;recommendations, and vote on information related to the premarket approval&lt;/font&gt;&lt;/p&gt;&lt;p class="MsoNoSpacing" style="margin: 0in 0in 0pt"&gt;&lt;font face="Calibri" color="#000000" size="3"&gt;application (PMA) for SOLESTA, sponsored by Oceana Therapeutics, Inc.&lt;/font&gt;&lt;/p&gt;&lt;p class="MsoNoSpacing" style="margin: 0in 0in 0pt"&gt;&lt;font face="Calibri" color="#000000" size="3"&gt;SOLESTA is indicated for the treatment of fecal incontinence in patients who&lt;/font&gt;&lt;/p&gt;&lt;p class="MsoNoSpacing" style="margin: 0in 0in 0pt"&gt;&lt;font face="Calibri" color="#000000" size="3"&gt;have failed conservative therapy. On December 3, 2010, the committee will&lt;/font&gt;&lt;/p&gt;&lt;p class="MsoNoSpacing" style="margin: 0in 0in 0pt"&gt;&lt;font face="Calibri" color="#000000" size="3"&gt;discuss, make recommendations, and vote on information related to the PMA&lt;/font&gt;&lt;/p&gt;&lt;p class="MsoNoSpacing" style="margin: 0in 0in 0pt"&gt;&lt;font face="Calibri" color="#000000" size="3"&gt;for the LAP-BAND Adjustable Gastric Banding System, sponsored by Allergan.&lt;/font&gt;&lt;/p&gt;&lt;p class="MsoNoSpacing" style="margin: 0in 0in 0pt"&gt;&lt;font face="Calibri" color="#000000" size="3"&gt;The sponsor is requesting an expanded Indication for Use for their LAP-BAND&lt;/font&gt;&lt;/p&gt;&lt;p class="MsoNoSpacing" style="margin: 0in 0in 0pt"&gt;&lt;font face="Calibri" color="#000000" size="3"&gt;Adjustable Gastric Banding System to include weight reduction in patients&lt;/font&gt;&lt;/p&gt;&lt;p class="MsoNoSpacing" style="margin: 0in 0in 0pt"&gt;&lt;font color="#000000"&gt;&lt;font face="Calibri"&gt;&lt;font size="3"&gt;with a Body Mass Index (BMI) of at least 35 kg/m&lt;/font&gt;&lt;span style="font-size: 7.5pt"&gt;2 &lt;/span&gt;&lt;font size="3"&gt;or a BMI of at least 30&lt;/font&gt;&lt;/font&gt;&lt;/font&gt;&lt;/p&gt;&lt;p class="MsoNoSpacing" style="margin: 0in 0in 0pt"&gt;&lt;font color="#000000"&gt;&lt;font face="Calibri"&gt;&lt;font size="3"&gt;kg/m&lt;/font&gt;&lt;span style="font-size: 7.5pt"&gt;2 &lt;/span&gt;&lt;font size="3"&gt;with one or more comorbid conditions.&lt;/font&gt;&lt;/font&gt;&lt;/font&gt;&lt;/p&gt;&lt;p class="MsoNoSpacing" style="margin: 0in 0in 0pt"&gt;&lt;font face="Calibri" color="#000000" size="3"&gt;FDA intends to make background material available to the public no later&lt;/font&gt;&lt;/p&gt;&lt;p class="MsoNoSpacing" style="margin: 0in 0in 0pt"&gt;&lt;font face="Calibri" color="#000000" size="3"&gt;than 2 business days before the meeting. If FDA is unable to post the&lt;/font&gt;&lt;/p&gt;&lt;p class="MsoNoSpacing" style="margin: 0in 0in 0pt"&gt;&lt;font face="Calibri" color="#000000" size="3"&gt;background material on its Web site prior to the meeting, the background&lt;/font&gt;&lt;/p&gt;&lt;p class="MsoNoSpacing" style="margin: 0in 0in 0pt"&gt;&lt;font face="Calibri" color="#000000" size="3"&gt;material will be made publicly available at the location of the advisory&lt;/font&gt;&lt;/p&gt;&lt;p class="MsoNoSpacing" style="margin: 0in 0in 0pt"&gt;&lt;font face="Calibri" color="#000000" size="3"&gt;committee meeting, and the background material will be posted on FDA&amp;rsquo;s Web&lt;/font&gt;&lt;/p&gt;&lt;p class="MsoNoSpacing" style="margin: 0in 0in 0pt"&gt;&lt;font size="3"&gt;&lt;font color="#000000"&gt;&lt;font face="Calibri"&gt;site after the meeting. Background material is available at &lt;i&gt;http://www.fda.gov/&lt;o:p&gt;&lt;/o:p&gt;&lt;/i&gt;&lt;/font&gt;&lt;/font&gt;&lt;/font&gt;&lt;/p&gt;&lt;p class="MsoNoSpacing" style="margin: 0in 0in 0pt"&gt;&lt;font size="3"&gt;&lt;font color="#000000"&gt;&lt;font face="Calibri"&gt;&lt;i&gt;AdvisoryCommittees/Calendar/default.htm&lt;/i&gt;. Scroll down to the appropriate&lt;/font&gt;&lt;/font&gt;&lt;/font&gt;&lt;/p&gt;&lt;p class="MsoNoSpacing" style="margin: 0in 0in 0pt"&gt;&lt;font face="Calibri" color="#000000" size="3"&gt;advisory committee link.&lt;/font&gt;&lt;/p&gt;&lt;p class="MsoNoSpacing" style="margin: 0in 0in 0pt"&gt;&lt;font size="3"&gt;&lt;font color="#000000"&gt;&lt;font face="Calibri"&gt;&lt;i&gt;Procedure&lt;/i&gt;: Interested persons may present data, information, or views,&lt;/font&gt;&lt;/font&gt;&lt;/font&gt;&lt;/p&gt;&lt;p class="MsoNoSpacing" style="margin: 0in 0in 0pt"&gt;&lt;font face="Calibri" color="#000000" size="3"&gt;orally or in writing, on issues pending before the committee. Written&lt;/font&gt;&lt;/p&gt;&lt;p class="MsoNoSpacing" style="margin: 0in 0in 0pt"&gt;&lt;font face="Calibri" color="#000000" size="3"&gt;submissions may be made to the contact person on or before November 18,&lt;/font&gt;&lt;/p&gt;&lt;p class="MsoNoSpacing" style="margin: 0in 0in 0pt"&gt;&lt;font face="Calibri" color="#000000" size="3"&gt;2010. Oral presentations from the public will be scheduled between&lt;/font&gt;&lt;/p&gt;&lt;p class="MsoNoSpacing" style="margin: 0in 0in 0pt"&gt;&lt;font face="Calibri" color="#000000" size="3"&gt;approximately 1 p.m. and 2 p.m. on December 2 and 3, 2010. Those desiring&lt;/font&gt;&lt;/p&gt;&lt;p class="MsoNoSpacing" style="margin: 0in 0in 0pt"&gt;&lt;font face="Calibri" color="#000000" size="3"&gt;to make formal oral presentations should notify the contact person and submit&lt;/font&gt;&lt;/p&gt;&lt;p class="MsoNoSpacing" style="margin: 0in 0in 0pt"&gt;&lt;font face="Calibri" color="#000000" size="3"&gt;a brief statement of the general nature of the evidence or arguments they wish&lt;/font&gt;&lt;/p&gt;&lt;p class="MsoNoSpacing" style="margin: 0in 0in 0pt"&gt;&lt;font face="Calibri" color="#000000" size="3"&gt;to present, the names and addresses of proposed participants, and an&lt;/font&gt;&lt;/p&gt;&lt;p class="MsoNoSpacing" style="margin: 0in 0in 0pt"&gt;&lt;font face="Calibri" color="#000000" size="3"&gt;indication of the approximate time requested to make their presentation on&lt;/font&gt;&lt;/p&gt;&lt;p class="MsoNoSpacing" style="margin: 0in 0in 0pt"&gt;&lt;font face="Calibri" color="#000000" size="3"&gt;or before November 10, 2010. Time allotted for each presentation may be&lt;/font&gt;&lt;/p&gt;&lt;p class="MsoNoSpacing" style="margin: 0in 0in 0pt"&gt;&lt;font face="Calibri" color="#000000" size="3"&gt;limited. If the number of registrants requesting to speak is greater than can&lt;/font&gt;&lt;/p&gt;&lt;p class="MsoNoSpacing" style="margin: 0in 0in 0pt"&gt;&lt;font face="Calibri" color="#000000" size="3"&gt;be reasonably accommodated during the scheduled open public hearing&lt;/font&gt;&lt;/p&gt;&lt;p class="MsoNoSpacing" style="margin: 0in 0in 0pt"&gt;&lt;font face="Calibri" color="#000000" size="3"&gt;session, FDA may conduct a lottery to determine the speakers for the&lt;/font&gt;&lt;/p&gt;&lt;p class="MsoNoSpacing" style="margin: 0in 0in 0pt"&gt;&lt;font face="Calibri" color="#000000" size="3"&gt;scheduled open public hearing session. The contact person will notify&lt;/font&gt;&lt;/p&gt;&lt;p class="MsoNoSpacing" style="margin: 0in 0in 0pt"&gt;&lt;font face="Calibri" color="#000000" size="3"&gt;interested persons regarding their request to speak by November 11, 2010.&lt;/font&gt;&lt;/p&gt;&lt;p class="MsoNoSpacing" style="margin: 0in 0in 0pt"&gt;&lt;font face="Calibri" color="#000000" size="3"&gt;Persons attending FDA&amp;rsquo;s advisory committee meetings are advised that the&lt;/font&gt;&lt;/p&gt;&lt;p class="MsoNoSpacing" style="margin: 0in 0in 0pt"&gt;&lt;font face="Calibri" color="#000000" size="3"&gt;agency is not responsible for providing access to electrical outlets.&lt;/font&gt;&lt;/p&gt;&lt;p class="MsoNoSpacing" style="margin: 0in 0in 0pt"&gt;&lt;font face="Calibri" color="#000000" size="3"&gt;FDA welcomes the attendance of the public at its advisory committee&lt;/font&gt;&lt;/p&gt;&lt;p class="MsoNoSpacing" style="margin: 0in 0in 0pt"&gt;&lt;font face="Calibri" color="#000000" size="3"&gt;meetings and will make every effort to accommodate persons with physical&lt;/font&gt;&lt;/p&gt;&lt;p class="MsoNoSpacing" style="margin: 0in 0in 0pt"&gt;&lt;font face="Calibri" color="#000000" size="3"&gt;disabilities or special needs. If you require special accommodations due to a&lt;/font&gt;&lt;/p&gt;&lt;p class="MsoNoSpacing" style="margin: 0in 0in 0pt"&gt;&lt;font face="Calibri" color="#000000" size="3"&gt;disability, please contact AnnMarie Williams, Conference Management Staff,&lt;/font&gt;&lt;/p&gt;&lt;p class="MsoNoSpacing" style="margin: 0in 0in 0pt"&gt;&lt;font face="Calibri" color="#000000" size="3"&gt;301&amp;ndash;796&amp;ndash;5966, at least 7 days in advance of the meeting.&lt;/font&gt;&lt;/p&gt;&lt;p class="MsoNoSpacing" style="margin: 0in 0in 0pt"&gt;&lt;font face="Calibri" color="#000000" size="3"&gt;FDA is committed to the orderly conduct of its advisory committee&lt;/font&gt;&lt;/p&gt;&lt;p class="MsoNoSpacing" style="margin: 0in 0in 0pt"&gt;&lt;font size="3"&gt;&lt;font color="#000000"&gt;&lt;font face="Calibri"&gt;meetings. Please visit our Web site at &lt;i&gt;http://www.fda.gov/AdvisoryCommittees/&lt;o:p&gt;&lt;/o:p&gt;&lt;/i&gt;&lt;/font&gt;&lt;/font&gt;&lt;/font&gt;&lt;/p&gt;&lt;p class="MsoNoSpacing" style="margin: 0in 0in 0pt"&gt;&lt;font size="3"&gt;&lt;font color="#000000"&gt;&lt;font face="Calibri"&gt;&lt;i&gt;AboutAdvisoryCommittees/ucm111462.htm &lt;/i&gt;for procedures on public conduct&lt;/font&gt;&lt;/font&gt;&lt;/font&gt;&lt;/p&gt;&lt;p class="MsoNoSpacing" style="margin: 0in 0in 0pt"&gt;&lt;font face="Calibri" color="#000000" size="3"&gt;during advisory committee meetings.&lt;/font&gt;&lt;/p&gt;&lt;p class="MsoNoSpacing" style="margin: 0in 0in 0pt"&gt;&lt;font face="Calibri" color="#000000" size="3"&gt;Notice of this meeting is given under the Federal Advisory Committee Act&lt;/font&gt;&lt;/p&gt;&lt;p class="MsoNoSpacing" style="margin: 0in 0in 0pt"&gt;&lt;font face="Calibri" color="#000000" size="3"&gt;(5 U.S.C. app. 2).&lt;/font&gt;&lt;/p&gt;&lt;p class="MsoNoSpacing" style="margin: 0in 0in 0pt"&gt;&lt;b&gt;&lt;span style="font-size: 18pt; color: #484138; mso-bidi-font-family: Arial"&gt;&lt;font face="Calibri"&gt;&amp;nbsp;&lt;o:p&gt;&lt;/o:p&gt;&lt;/font&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p class="MsoNoSpacing" style="margin: 0in 0in 0pt"&gt;&lt;span style="font-size: 9.5pt; color: #484138; mso-bidi-font-family: Arial"&gt;&lt;font face="Calibri"&gt;Dated: September 17, 2010.&lt;o:p&gt;&lt;/o:p&gt;&lt;/font&gt;&lt;/span&gt;&lt;/p&gt;&lt;p class="MsoNoSpacing" style="margin: 0in 0in 0pt"&gt;&lt;b&gt;&lt;span style="font-size: 9.5pt; color: #484138; mso-bidi-font-family: Arial"&gt;&lt;font face="Calibri"&gt;Jill Hartzler Warner,&lt;o:p&gt;&lt;/o:p&gt;&lt;/font&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p class="MsoNoSpacing" style="margin: 0in 0in 0pt"&gt;&lt;i&gt;&lt;span style="font-size: 9.5pt; color: #484138; mso-bidi-font-family: Arial"&gt;&lt;font face="Calibri"&gt;Acting Associate Commissioner for Special Medical Programs.&lt;o:p&gt;&lt;/o:p&gt;&lt;/font&gt;&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;/font&gt;&lt;/p&gt;</wcm:element>
</wcm:root>
